Industries > Pharma > Vaccines Sales Market Report 2020-2030
Vaccines Sales Market Report 2020-2030
Forecasts by Disease Type (Viral Diseases, Bacterial Diseases), Viral Diseases (Hepatitis, Influenza, Human Papillomavirus, Measles/Mumps/Rubella, Rotavirus, Other Viral Diseases), Bacterial Disease (Pneumococcal Disease, Meningococcal Disease, Diphtheria/Tetanus/Pertussis, Other Bacterial Disease), Type of Vaccines (Recombinant/Conjugate/Subunit, Inactivated, Live Attenuated, Toxoid), Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, Other Distribution Channel), Age Group (Paediatrics, Adults, Other Age Groups), Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa), Competitive Landscape PLUS COVID-19 Impact Analysis and Profiles of Leading Vaccines Sales Companies
Vaccine Sales Market–our new study reveals trends, R&D progress, and predicted revenues
Where is the Vaccines market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.
Discover how to stay ahead
Our 602 pages report provides 400+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Vaccines Market. See how to exploit the opportunities.
Forecasts to 2030 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), product profiles and commercial developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.
To access the data contained in this document please email contactus@visiongain.com
Discover sales predictions for the world market and submarkets
Report Scope
• Disease Type
– Viral Diseases
– Bacterial Diseases
• Viral Diseases
– Hepatitis
– Influenza
– Human Papillomavirus
– Measles/Mumps/Rubella
– Rotavirus
– Other Viral Diseases
• Bacterial Disease
– Pneumococcal Disease
– Meningococcal Disease
– Diphtheria/Tetanus/Pertussis
– Other Bacterial Disease
• Type Vaccines
– Recombinant/Conjugate/Subunit
– Inactivated
– Live Attenuated
– Toxoid
• Distribution Channel
– Hospital & Retail Pharmacies
– Government Suppliers
– Other Distribution Channel
• Age Group
– Paediatrics
– Adults
– Other Age Groups
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 19 leading national markets:
• North America
– U.S.
– Canada
• Europe
– Germany
– UK
– France
– Italy
– Russia
– Rest of Europe
• Asia Pacific
– Japan
– China
– India
– South Korea
– Australia
– Rest of Asia Pacific
• Middle East and Africa
– Saudi Arabia
– South Africa
– Iran
– UAE
– Nigeria
– Rest of Middle East and Africa
• Latin America
– Brazil
– Mexico
– Rest of Latin America
Brazil Vaccine Sales Market Outlook
The Brazilian human vaccines market is the largest in Latin America. Brazil has been an important developing market, especially in its region. However current economic and political instabilities have made is a little bit weary. Nonetheless, Brazil still possesses the characteristic of an emerging country to have a growing middle class who are determined to get better access to healthcare. The progress of healthcare has increased the life expectancy of people in Brazil, leading to a growing elderly population that demand vaccines.
Brazil vaccines market was valued at US$ xx billion in 2019 and is projected to reach at a market value of US$ xx billion by 2030. Brazil market is expected to grow at a CAGR of xx% during the forecast period 2020-2030. The market is estimated to grow at a CAGR of xx% in the first half period 2020-2025 and is projected to grow at CAGR of xx% in the other half period 2025-2030.
This report forecasts that the global vaccine market is expected to grow steadily during the forecast period from 2020 to 2030. This will be driven by an ageing population and an increase in the incidence of chronic diseases that increase the risk of infection in human immune systems. Furthermore, as your economies become prosperous, your spending on health care increases, the demand from emerging markets will increase. The travel industry will also help sustain growth on the vaccine market, with higher revenues from the adult vaccine subservice resulting from increased awareness about vaccinating benefits for a country’s workforce.
As treatment options become more innovative, businesses will strive to remove the cold chain from their supply logistics, cut costs, and make it easier to supplies vaccines in different climates and regions, the future of the human vaccine market looks very promising. Several innovative vaccines are on the market in the pipeline. These vaccines are progressive improvements in vaccine efficacy, coverage through more disease strains and viable therapy against previously untreatable illnesses. This will help address a larger group of people with different health requirements, thereby increasing access and coverage of vaccinations.
Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general. The growth will highlight the importance of vaccines to the global population’s health and the potential advantages for the global economy between 2020 and 2030.
Companies Profiled in the Report
• AstraZeneca
• Bavarian Nordic
• Bayer
• BiondVax
• Bristol-Myers Squibb
• Eli Lilly
• Emergent BioSolutionsInc
• Fresenius
• GlaxoSmithKline (GSK)
• Johnson & Johnson
• Merck & Co.
• Pfizer
• Roche
• Sanofi Pasteur
• Takeda
The Vaccines Market Pipeline Analysis
• A SWOT and STEP analysis of the global vaccines market
• Key Questions Answered by this Report:
• What is the current size of the overall global human vaccines market? How much will this market be worth from 2020 to 2030?
• What are the main drivers and restraints that will shape the overall vaccines market over the next ten years?
• What are the main segments within the overall human vaccines market? How much will each of these segments be worth for the period 2020 to 2030? How will the composition of the market change during that time, and why?
• What factors will affect that industry and market over the next ten years?
• What are the largest national markets for the world vaccines? What is their current status and how will they develop over the next ten years? What are their revenue potentials to 2030?
• How will political and regulatory forces influence regional markets?
• How will market shares of the leading national markets change by 2030, and which geographical region will lead the market in 2030?
• Who are the leading companies and what are their activities, results, developments, and prospects?
• What are the leading vaccines? What are their revenues and latest developments?
• What are some of the most prominent human vaccines currently in development?
• What are the main trends that will affect the world vaccines market between 2020 and 2030?
• What are the main strengths, weaknesses, opportunities, and threats for the market?
• What are the social, technological, economic, and political influences that will shape that industry over the next ten years?
• How will the global vaccines market evolve over the forecasted period, 2020 to 2030?
• How will the market shares for each checkpoint inhibitor anti-cancer treatment submarket develop from 2020 to 2030?
• Which therapies can succeed and what revenues could they generate to 2030?
• What will be the main commercial drivers for the market from 2020 to 2030?
• How will market shares of prominent national markets change from 2020, and which countries will lead the market in 2030, achieving highest revenues and fastest growth?
• How will that industry evolve between 2020 and 2030, especially in R&D?
Visiongain’s study is intended for anyone requiring commercial analyses for the Global Vaccines Sales Market. You find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Vaccines Sales Market Analysis : Forecasts by Disease Type (Viral Diseases, Bacterial Diseases), Viral Diseases (Hepatitis, Influenza, Human Papillomavirus, Measles/Mumps/Rubella, Rotavirus, Other Viral Diseases), Bacterial Disease (Pneumococcal Disease, Meningococcal Disease, Diphtheria/Tetanus/Pertussis, Other Bacterial Disease), Type of Vaccines (Recombinant/Conjugate/Subunit, Inactivated, Live Attenuated, Toxoid), Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, Other Distribution Channel), Age Group (Paediatrics, Adults, Other Age Groups), Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa), Competitive Landscape PLUS COVID-19 Impact Analysis and Profiles of Leading Vaccines Sales Companies. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 Why You Should Buy This Report
1.2 How This Report Delivers
1.3 Key Questions Answered by This Analytical Report Include:
1.4 Who is This Report For?
1.5 Methodology
1.5.1 Primary Research
1.5.2 Secondary Research
1.5.3 Data Sources
1.6 Market Evaluation & Forecasting Methodology
1.7 COIVD-19 Impact Recovery Pattern Analysis
1.7.1 V-Shaped Recovery
1.7.2 U-Shaped Recovery
1.7.3 W-Shaped Recovery
1.7.4 L-Shaped Recovery
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Executive Summary
2.1.1 Growing Demand for Bacterial Type to Dominate the Market
2.1.1.1 Due to higher sales of pneumococcal, meningitis and DTP worldwide, the segment of bacterial diseases has a dominant market share
2.1.2 By Age Group Analysis
2.1.3 By Distribution Channel Analysis
2.1.4 Regional Market Insight
3. Vaccine Industry Overview
3.1 Industry Definitions
3.2 Immune System and Vaccines
3.3 How Vaccines Work
3.4 Types of Immunity
3.4.1 Active Immunity
3.4.2 Passive Immunity
3.4.3 Advantages of Vaccination
3.5 History of Vaccines
3.6 Rapid Manufacturing for Pandemics
3.6.1 Types of Vaccine Manufacturing Methods
4. Market Dynamics
4.1 Vaccine Development and Distribution Amid the COVID-19 Pandemic
4.2 Market Growth Driving Factors
4.2.1 Growing Vaccines Supply by UNICEF, WHO, PAHO to Aid Immunization Process
4.2.2 Strong Supply Backed Up by Robust R&D to Drive the Market
4.2.3 Competitive Pipeline to Expand the Market Value During the Forecast Period
4.2.4 Technological Advancements such as Rapid Manufacturing and Others
4.2.5 Rising Immunization Across the Globe
4.2.6 Government Support for Vaccine Development
4.3 Market Growth Restraining Factors
4.3.1 High Cost Associated with Vaccine Dose to Limit Adoption
4.3.2 Lack of Awareness in Low-Income Countries
4.3.1 High Prices of Vaccines
4.3.1 Rising Concerns of Associated Risk Factors
4.3.2 Inadequate Vaccine Supply
4.4 Growth Opportunities in the Global Market
4.4.1 RNA Vaccination
4.4.2 Rise of Antibiotic Resistance
4.4.3 Current Situation
4.4.4 Development and Launch of New Vaccines
4.4.5 Increased R&D Efforts
4.4.6 Increased Demand from Emerging Markets
4.4.7 Government Initiatives for Increased Immunizations
4.4.8 Global Alliance for Vaccines and Immunization (GAVI)
4.4.9 Improving access to sustainable immunization services.
4.4.10 Undulating Demand
4.4.11 Supply Restraints
4.4.12 Funding Trends
4.4.13 Protecting the Workforce of an Economy
4.5 SWOT Analysis of the World Human Vaccines Market
4.5.1 Strengths
4.5.2 Weaknesses
4.5.3 Opportunities
4.5.4 Threats
4.6 STEP Analysis of the World Human Vaccines Industry and Market
4.6.1 Social Factors
4.6.2 Technological Forces
4.6.3 Economic Factors
4.6.4 Political Factors
5. COVID-19 Impact Analysis
5.1 Research and Development on COVID-19
6. Global Vaccines Sales Market Outlook
6.1 Market Overview
6.2 Market in Terms of Value
6.2.1 Market in Terms of Value (Normal Recovery)
6.2.2 Market in Terms of Value (V-Shaped Recovery)
6.2.3 Market in Terms of Value (W-Shaped Recovery)
6.2.4 Market in Terms of Value (U-Shaped Recovery)
6.3 Global Market Breakdown by Region
6.3.1.1 North America is expected to dominate the global market during the forecast period
6.3.1 Market in Terms of Value (Normal Recovery)
6.3.2 Market in Terms of Value (V-Shaped Recovery)
6.3.3 Market in Terms of Value (W-Shaped Recovery)
6.3.4 Market in Terms of Value (U-Shaped Recovery)
6.3.5 Market in Terms of Value (L-Shaped Recovery)
6.4 Global Market Breakdown by Disease Type
6.4.1.1 Bacterial Diseases the segment held the significant share in the overall market and is expected to offer an opportunity throughout the forecast period
6.4.1 Market in Terms of Value (Normal Recovery)
6.4.2 Market in Terms of Value (V-Shaped Recovery)
6.4.3 Market in Terms of Value (W-Shaped Recovery)
6.4.4 Market in Terms of Value (U-Shaped Recovery)
6.4.5 Market in Terms of Value (L-Shaped Recovery)
6.5 Global Market Breakdown by Viral Diseases
6.5.1.1 Hepatitis Segment is expected to have the highest CAGR during forecast period.
6.5.1 Human Diseases
6.5.1 Market in Terms of Value (Normal Recovery)
6.5.2 Market in Terms of Value (V-Shaped Recovery)
6.5.3 Market in Terms of Value (W-Shaped Recovery)
6.5.4 Market in Terms of Value (U-Shaped Recovery)
6.5.5 Market in Terms of Value (L-Shaped Recovery)
6.6 Global Market Breakdown by Vaccine Type
6.6.1 Recombinant/Conjugate/Subunit the segment held the significant share
6.6.2 Inactivated (Killed) Vaccines
6.6.3 Toxoid Vaccines
6.6.4 Subunit Vaccines
6.6.5 Conjugate Vaccines
6.6.6 Recombinant Vector Vaccines
6.6.7 DNA Vaccines
6.6.8 RNA Vaccines
6.6.9 Adjuvants and Excipients
6.6.10 Pathogen Components
6.6.11 Particulate Adjuvants
6.6.12 Other/Combination Vaccines
6.6.13 Market in Terms of Value (Normal Recovery)
6.6.14 Market in Terms of Value (V-Shaped Recovery)
6.6.15 Market in Terms of Value (W-Shaped Recovery)
6.6.16 Market in Terms of Value (U-Shaped Recovery)
6.6.17 Market in Terms of Value (L-Shaped Recovery)
6.7 Global Market Breakdown by Bacterial Disease
6.7.1.1 Pneumococcal Disease is expected to offer an opportunity throughout the forecast period
6.7.1 Market in Terms of Value (Normal Recovery)
6.7.2 Market in Terms of Value (V-Shaped Recovery)
6.7.3 Market in Terms of Value (W-Shaped Recovery)
6.7.4 Market in Terms of Value (U-Shaped Recovery)
6.7.5 Market in Terms of Value (L-Shaped Recovery)
6.8 Global Market Breakdown by Distribution Channel
6.8.1.1 A dominant share of the income is anticipated for hospital and retail pharmacies
6.8.1 Market in Terms of Value (Normal Recovery)
6.8.2 Market in Terms of Value (V-Shaped Recovery)
6.8.3 Market in Terms of Value (W-Shaped Recovery)
6.8.4 Market in Terms of Value (U-Shaped Recovery)
6.8.5 Market in Terms of Value (L-Shaped Recovery)
6.9 Global Market Breakdown by Age Group
6.9.1 Pediatric Vaccines
6.9.2 Paediatric Vaccine Trends
6.9.3 Prenatal Vaccines
6.9.4 Market in Terms of Value (Normal Recovery)
6.9.5 Market in Terms of Value (V-Shaped Recovery)
6.9.6 Market in Terms of Value (W-Shaped Recovery)
6.9.7 Market in Terms of Value (U-Shaped Recovery)
6.9.8 Market in Terms of Value (L-Shaped Recovery)
7. North America Vaccines Sales Market Outlook
7.1.1 Growth attributed to vaccination compulsion or mandate
7.1 North America Market Overview
7.2 North America Market in Terms of Value
7.2.1 Market in Terms of Value (Normal Recovery)
7.2.2 Market in Terms of Value (V-Shaped Recovery)
7.2.3 Market in Terms of Value (W-Shaped Recovery)
7.2.4 Market in Terms of Value (U-Shaped Recovery)
7.2.5 Market in Terms of Value (L-Shaped Recovery)
7.3 North America Market Breakdown by Country
7.3.1 Market in Terms of Value (Normal Recovery)
7.3.2 Market in Terms of Value (V-Shaped Recovery)
7.3.3 Market in Terms of Value (W-Shaped Recovery)
7.3.4 Market in Terms of Value (U-Shaped Recovery)
7.3.5 Market in Terms of Value (L-Shaped Recovery)
7.4 U.S. Vaccine Sales Market Outlook
7.4.1.1 The country is expected to offer an opportunity throughout the forecast period
7.4.1 Market in Terms of Value (Normal Recovery)
7.4.2 Market in Terms of Value (V-Shaped Recovery)
7.4.3 Market in Terms of Value (W-Shaped Recovery)
7.4.4 Market in Terms of Value (U-Shaped Recovery)
7.4.5 Market in Terms of Value (L-Shaped Recovery)
7.5 Canada Vaccine Sales Market Outlook
7.5.1.1 Market is supported by consistent and sustained funding of immunization programs
7.5.1 Market in Terms of Value (Normal Recovery)
7.5.2 Market in Terms of Value (V-Shaped Recovery)
7.5.3 Market in Terms of Value (W-Shaped Recovery)
7.5.4 Market in Terms of Value (U-Shaped Recovery)
7.5.5 Market in Terms of Value (L-Shaped Recovery)
7.6 North America Market Breakdown by Disease Type
7.6.1 Market in Terms of Value (Normal Recovery)
7.6.2 Market in Terms of Value (V-Shaped Recovery)
7.6.3 Market in Terms of Value (W-Shaped Recovery)
7.6.4 Market in Terms of Value (U-Shaped Recovery)
7.6.5 Market in Terms of Value (L-Shaped Recovery)
7.7 North America Market Breakdown by Viral Diseases
7.7.1 Market in Terms of Value (Normal Recovery)
7.7.2 Market in Terms of Value (V-Shaped Recovery)
7.7.3 Market in Terms of Value (W-Shaped Recovery)
7.7.4 Market in Terms of Value (U-Shaped Recovery)
7.7.5 Market in Terms of Value (L-Shaped Recovery)
7.8 North America Market Breakdown by Vaccine Type
7.8.1 Market in Terms of Value (Normal Recovery)
7.8.2 Market in Terms of Value (V-Shaped Recovery)
7.8.3 Market in Terms of Value (W-Shaped Recovery)
7.8.4 Market in Terms of Value (U-Shaped Recovery)
7.8.5 Market in Terms of Value (L-Shaped Recovery)
7.9 North America Market Breakdown by Bacterial Disease
7.9.1 Market in Terms of Value (Normal Recovery)
7.9.2 Market in Terms of Value (V-Shaped Recovery)
7.9.3 Market in Terms of Value (W-Shaped Recovery)
7.9.4 Market in Terms of Value (U-Shaped Recovery)
7.9.5 Market in Terms of Value (L-Shaped Recovery)
7.10 North America Market Breakdown by Distribution Channel
7.10.1 Market in Terms of Value (Normal Recovery)
7.10.2 Market in Terms of Value (V-Shaped Recovery)
7.10.3 Market in Terms of Value (W-Shaped Recovery)
7.10.4 Market in Terms of Value (U-Shaped Recovery)
7.10.5 Market in Terms of Value (L-Shaped Recovery)
7.11 North America Market Breakdown by Age Group
7.11.1 Market in Terms of Value (Normal Recovery)
7.11.2 Market in Terms of Value (V-Shaped Recovery)
7.11.3 Market in Terms of Value (W-Shaped Recovery)
7.11.4 Market in Terms of Value (U-Shaped Recovery)
7.11.5 Market in Terms of Value (L-Shaped Recovery)
8. Europe Vaccines Sales Market Outlook
8.1 Europe Market Overview
8.1.1 A considerable growth in the vaccine market is expected in the European region.
8.2 Europe Market in Terms of Value
8.2.1 Market in Terms of Value (Normal Recovery)
8.2.2 Market in Terms of Value (V-Shaped Recovery)
8.2.3 Market in Terms of Value (W-Shaped Recovery)
8.2.4 Market in Terms of Value (U-Shaped Recovery)
8.2.5 Market in Terms of Value (L-Shaped Recovery)
8.3 Europe Market Breakdown by Country
8.3.1 Market in Terms of Value (Normal Recovery)
8.3.2 Market in Terms of Value (V-Shaped Recovery)
8.3.3 Market in Terms of Value (W-Shaped Recovery)
8.3.4 Market in Terms of Value (U-Shaped Recovery)
8.3.5 Market in Terms of Value (L-Shaped Recovery)
8.4 Russia Vaccine Sales Market Outlook
8.4.1.1 The Russian Federation has purchased over 90% of the total supply of the vaccines in the market
8.4.1 Market in Terms of Value (Normal Recovery)
8.4.2 Market in Terms of Value (V-Shaped Recovery)
8.4.3 Market in Terms of Value (W-Shaped Recovery)
8.4.4 Market in Terms of Value (U-Shaped Recovery)
8.4.5 Market in Terms of Value (L-Shaped Recovery)
8.5 Germany Vaccine Sales Market Outlook
8.5.1.1 Germany is expected to offer an opportunity throughout the forecast period.
8.5.1 Market in Terms of Value (Normal Recovery)
8.5.2 Market in Terms of Value (V-Shaped Recovery)
8.5.3 Market in Terms of Value (W-Shaped Recovery)
8.5.4 Market in Terms of Value (U-Shaped Recovery)
8.5.5 Market in Terms of Value (L-Shaped Recovery)
8.6 UK Vaccine Sales Market Outlook
8.6.1.1 The U.K. is one of the major contributors to the vaccine market
8.6.1 Market in Terms of Value (Normal Recovery)
8.6.1 Market in Terms of Value (V-Shaped Recovery)
8.6.2 Market in Terms of Value (W-Shaped Recovery)
8.6.3 Market in Terms of Value (U-Shaped Recovery)
8.6.4 Market in Terms of Value (L-Shaped Recovery)
8.7 France Vaccine Sales Market Outlook
8.7.1.1 France is one of the major countries to produce vaccines
8.7.1 Market in Terms of Value (Normal Recovery)
8.7.2 Market in Terms of Value (V-Shaped Recovery)
8.7.3 Market in Terms of Value (W-Shaped Recovery)
8.7.4 Market in Terms of Value (U-Shaped Recovery)
8.7.5 Market in Terms of Value (L-Shaped Recovery)
8.8 Italy Vaccine Sales Market Outlook
8.8.1.1 Italy is the fourth largest market for human vaccines within Europe
8.8.1 Market in Terms of Value (Normal Recovery)
8.8.2 Market in Terms of Value (V-Shaped Recovery)
8.8.3 Market in Terms of Value (W-Shaped Recovery)
8.8.4 Market in Terms of Value (U-Shaped Recovery)
8.8.5 Market in Terms of Value (L-Shaped Recovery)
8.9 Rest of Europe Vaccine Sales Market Outlook
8.9.1 Market in Terms of Value (Normal Recovery)
8.9.2 Market in Terms of Value (V-Shaped Recovery)
8.9.3 Market in Terms of Value (W-Shaped Recovery)
8.9.4 Market in Terms of Value (U-Shaped Recovery)
8.9.5 Market in Terms of Value (L-Shaped Recovery)
8.10 Europe Market Breakdown by Disease Type
8.10.1 Market in Terms of Value (Normal Recovery)
8.10.2 Market in Terms of Value (V-Shaped Recovery)
8.10.3 Market in Terms of Value (W-Shaped Recovery)
8.10.4 Market in Terms of Value (U-Shaped Recovery)
8.10.5 Market in Terms of Value (L-Shaped Recovery)
8.11 Europe Market Breakdown by Viral Disease
8.11.1 Market in Terms of Value (Normal Recovery)
8.11.2 Market in Terms of Value (V-Shaped Recovery)
8.11.3 Market in Terms of Value (W-Shaped Recovery)
8.11.4 Market in Terms of Value (U-Shaped Recovery)
8.11.5 Market in Terms of Value (L-Shaped Recovery)
8.12 Europe Market Breakdown by Vaccine Type
8.12.1 Market in Terms of Value (Normal Recovery)
8.12.2 Market in Terms of Value (V-Shaped Recovery)
8.12.3 Market in Terms of Value (W-Shaped Recovery)
8.12.4 Market in Terms of Value (U-Shaped Recovery)
8.12.5 Market in Terms of Value (L-Shaped Recovery)
8.13 Europe Market Breakdown by Bacterial Disease
8.13.1 Market in Terms of Value (Normal Recovery)
8.13.2 Market in Terms of Value (V-Shaped Recovery)
8.13.3 Market in Terms of Value (W-Shaped Recovery)
8.13.4 Market in Terms of Value (U-Shaped Recovery)
8.13.5 Market in Terms of Value (L-Shaped Recovery)
8.14 Europe Market Breakdown by Distribution Channel
8.14.1 Market in Terms of Value (Normal Recovery)
8.14.2 Market in Terms of Value (V-Shaped Recovery)
8.14.3 Market in Terms of Value (W-Shaped Recovery)
8.14.4 Market in Terms of Value (U-Shaped Recovery)
8.14.5 Market in Terms of Value (L-Shaped Recovery)
8.15 Europe Market Breakdown by Age Group
8.15.1 Market in Terms of Value (Normal Recovery)
8.15.2 Market in Terms of Value (V-Shaped Recovery)
8.15.3 Market in Terms of Value (W-Shaped Recovery)
8.15.4 Market in Terms of Value (U-Shaped Recovery)
8.15.5 Market in Terms of Value (L-Shaped Recovery)
9. Asia-Pacific Vaccines Sales Market Outlook
9.1 Asia-Pacific Market Overview
9.2 Asia-Pacific Market in Terms of Value
9.2.1 Market in Terms of Value (Normal Recovery)
9.2.2 Market in Terms of Value (V-Shaped Recovery)
9.2.3 Market in Terms of Value (W-Shaped Recovery)
9.2.4 Market in Terms of Value (U-Shaped Recovery)
9.2.5 Market in Terms of Value (L-Shaped Recovery)
9.3 Asia-Pacific Market Breakdown by Country
9.3.1 Market in Terms of Value (Normal Recovery)
9.3.2 Market in Terms of Value (V-Shaped Recovery)
9.3.3 Market in Terms of Value (W-Shaped Recovery)
9.3.4 Market in Terms of Value (U-Shaped Recovery)
9.3.5 Market in Terms of Value (L-Shaped Recovery)
9.4 China Vaccine Sales Market Outlook
9.4.1.1 Growth prospects remain strong in the country
9.4.1 Market in Terms of Value (Normal Recovery)
9.4.2 Market in Terms of Value (V-Shaped Recovery)
9.4.3 Market in Terms of Value (W-Shaped Recovery)
9.4.4 Market in Terms of Value (U-Shaped Recovery)
9.4.5 Market in Terms of Value (L-Shaped Recovery)
9.5 Japan Vaccine Sales Market Outlook
9.5.1.1 Japan is expected to offer an opportunity throughout the forecast period
9.5.1 Market in Terms of Value (Normal Recovery)
9.5.2 Market in Terms of Value (V-Shaped Recovery)
9.5.3 Market in Terms of Value (W-Shaped Recovery)
9.5.4 Market in Terms of Value (U-Shaped Recovery)
9.5.5 Market in Terms of Value (L-Shaped Recovery)
9.6 India Vaccine Sales Market Outlook
9.6.1.1 The prevalence of the diseases has been quite high in India, which is driving the market growth
9.6.1 Market in Terms of Value (Normal Recovery)
9.6.2 Market in Terms of Value (V-Shaped Recovery)
9.6.3 Market in Terms of Value (W-Shaped Recovery)
9.6.4 Market in Terms of Value (U-Shaped Recovery)
9.6.5 Market in Terms of Value (L-Shaped Recovery)
9.7 South Korea Vaccine Sales Market Outlook
9.7.1.1 Korea has been importing all demand for this vaccine due to a lack of homegrown technology to develop a vaccine locally
9.7.1 Market in Terms of Value (Normal Recovery)
9.7.2 Market in Terms of Value (V-Shaped Recovery)
9.7.3 Market in Terms of Value (W-Shaped Recovery)
9.7.4 Market in Terms of Value (U-Shaped Recovery)
9.7.5 Market in Terms of Value (L-Shaped Recovery)
9.8 Australia Vaccine Sales Market Outlook
9.8.1.1 Australia is on track for a record number of flu vaccinations
9.8.1 Market in Terms of Value (Normal Recovery)
9.8.2 Market in Terms of Value (V-Shaped Recovery)
9.8.3 Market in Terms of Value (W-Shaped Recovery)
9.8.4 Market in Terms of Value (U-Shaped Recovery)
9.8.5 Market in Terms of Value (L-Shaped Recovery)
9.9 Rest of Asia-Pacific Vaccine Sales Market Outlook
9.9.1 Market in Terms of Value (Normal Recovery)
9.9.2 Market in Terms of Value (V-Shaped Recovery)
9.9.3 Market in Terms of Value (W-Shaped Recovery)
9.9.4 Market in Terms of Value (U-Shaped Recovery)
9.9.5 Market in Terms of Value (L-Shaped Recovery)
9.10 Asia-Pacific Market Breakdown by Disease Type
9.10.1 Market in Terms of Value (Normal Recovery)
9.10.2 Market in Terms of Value (V-Shaped Recovery)
9.10.3 Market in Terms of Value (W-Shaped Recovery)
9.10.4 Market in Terms of Value (U-Shaped Recovery)
9.10.5 Market in Terms of Value (L-Shaped Recovery)
9.11 Asia-Pacific Market Breakdown by Viral Diseases
9.11.1 Market in Terms of Value (Normal Recovery)
9.11.2 Market in Terms of Value (V-Shaped Recovery)
9.11.3 Market in Terms of Value (W-Shaped Recovery)
9.11.4 Market in Terms of Value (U-Shaped Recovery)
9.11.5 Market in Terms of Value (L-Shaped Recovery)
9.12 Asia-Pacific Market Breakdown by Vaccine Type
9.12.1 Market in Terms of Value (Normal Recovery)
9.12.2 Market in Terms of Value (V-Shaped Recovery)
9.12.3 Market in Terms of Value (W-Shaped Recovery)
9.12.4 Market in Terms of Value (U-Shaped Recovery)
9.12.5 Market in Terms of Value (L-Shaped Recovery)
9.13 Asia-Pacific Market Breakdown by Bacterial Disease
9.13.1 Market in Terms of Value (Normal Recovery)
9.13.2 Market in Terms of Value (V-Shaped Recovery)
9.13.3 Market in Terms of Value (W-Shaped Recovery)
9.13.4 Market in Terms of Value (U-Shaped Recovery)
9.13.5 Market in Terms of Value (L-Shaped Recovery)
9.14 Asia-Pacific Market Breakdown by Distribution Channel
9.14.1 Market in Terms of Value (Normal Recovery)
9.14.2 Market in Terms of Value (V-Shaped Recovery)
9.14.3 Market in Terms of Value (W-Shaped Recovery)
9.14.4 Market in Terms of Value (U-Shaped Recovery)
9.14.5 Market in Terms of Value (L-Shaped Recovery)
9.15 Asia-Pacific Market Breakdown by Age Group
9.15.1 Market in Terms of Value (Normal Recovery)
9.15.2 Market in Terms of Value (V-Shaped Recovery)
9.15.3 Market in Terms of Value (W-Shaped Recovery)
9.15.4 Market in Terms of Value (U-Shaped Recovery)
9.15.5 Market in Terms of Value (L-Shaped Recovery)
10. Middle East & Africa Vaccines Sales Market Outlook
10.1 Middle East & Africa Market Overview
10.2 Middle East & Africa Market in Terms of Value
10.2.1 Market in Terms of Value (Normal Recovery)
10.2.2 Market in Terms of Value (V-Shaped Recovery)
10.2.3 Market in Terms of Value (W-Shaped Recovery)
10.2.4 Market in Terms of Value (U-Shaped Recovery)
10.2.5 Market in Terms of Value (L-Shaped Recovery)
10.3 Middle East & Africa Market Breakdown by Country
10.3.1 Market in Terms of Value (Normal Recovery)
10.3.2 Market in Terms of Value (V-Shaped Recovery)
10.3.3 Market in Terms of Value (W-Shaped Recovery)
10.3.4 Market in Terms of Value (U-Shaped Recovery)
10.3.5 Market in Terms of Value (L-Shaped Recovery)
10.4 Turkey Vaccine Sales Market Outlook
10.4.1 Market in Terms of Value (Normal Recovery)
10.4.2 Market in Terms of Value (V-Shaped Recovery)
10.4.3 Market in Terms of Value (W-Shaped Recovery)
10.4.4 Market in Terms of Value (U-Shaped Recovery)
10.4.5 Market in Terms of Value (L-Shaped Recovery)
10.5 Saudi Arabia Vaccine Sales Market Outlook
10.5.1.1 Healthcare is the third largest beneficiary behind education and military
10.5.1 Market in Terms of Value (Normal Recovery)
10.5.2 Market in Terms of Value (V-Shaped Recovery)
10.5.3 Market in Terms of Value (W-Shaped Recovery)
10.5.4 Market in Terms of Value (U-Shaped Recovery)
10.5.5 Market in Terms of Value (L-Shaped Recovery)
10.6 South Africa Vaccine Sales Market Outlook
10.6.1.1 Pneumonia vaccine alone used up 40% of South Africa’s total budget for vaccines
10.6.1 Market in Terms of Value (Normal Recovery)
10.6.2 Market in Terms of Value (V-Shaped Recovery)
10.6.3 Market in Terms of Value (W-Shaped Recovery)
10.6.4 Market in Terms of Value (U-Shaped Recovery)
10.6.5 Market in Terms of Value (L-Shaped Recovery)
10.7 Iran Vaccine Sales Market Outlook
10.7.1.1. Iran's vaccine industry, has a long history and international reputation
10.7.1 Market in Terms of Value (Normal Recovery)
10.7.2 Market in Terms of Value (V-Shaped Recovery)
10.7.3 Market in Terms of Value (W-Shaped Recovery)
10.7.4 Market in Terms of Value (U-Shaped Recovery)
10.7.5 Market in Terms of Value (L-Shaped Recovery)
10.8 UAE Vaccine Sales Market Outlook
10.8.1 Market in Terms of Value (Normal Recovery)
10.8.2 Market in Terms of Value (V-Shaped Recovery)
10.8.3 Market in Terms of Value (W-Shaped Recovery)
10.8.4 Market in Terms of Value (U-Shaped Recovery)
10.8.5 Market in Terms of Value (L-Shaped Recovery)
10.9 Rest of Middle East & Africa Vaccine Sales Market Outlook
10.9.1 Market in Terms of Value (Normal Recovery)
10.9.2 Market in Terms of Value (V-Shaped Recovery)
10.9.3 Market in Terms of Value (W-Shaped Recovery)
10.9.4 Market in Terms of Value (U-Shaped Recovery)
10.9.5 Market in Terms of Value (L-Shaped Recovery)
10.10 Middle East & Africa Market Breakdown by Disease Type
10.10.1 Market in Terms of Value (Normal Recovery)
10.10.2 Market in Terms of Value (V-Shaped Recovery)
10.10.3 Market in Terms of Value (W-Shaped Recovery)
10.10.4 Market in Terms of Value (U-Shaped Recovery)
10.10.5 Market in Terms of Value (L-Shaped Recovery)
10.11 Middle East & Africa Market Breakdown by Viral Diseases
10.11.1 Market in Terms of Value (Normal Recovery)
10.11.2 Market in Terms of Value (V-Shaped Recovery)
10.11.3 Market in Terms of Value (W-Shaped Recovery)
10.11.4 Market in Terms of Value (U-Shaped Recovery)
10.11.5 Market in Terms of Value (L-Shaped Recovery)
10.12 Middle East & Africa Market Breakdown by Vaccine Type
10.12.1 Market in Terms of Value (Normal Recovery)
10.12.2 Market in Terms of Value (V-Shaped Recovery)
10.12.3 Market in Terms of Value (W-Shaped Recovery)
10.12.4 Market in Terms of Value (U-Shaped Recovery)
10.12.5 Market in Terms of Value (L-Shaped Recovery)
10.13 Middle East & Africa Market Breakdown by Bacterial Disease
10.13.1 Market in Terms of Value (Normal Recovery)
10.13.2 Market in Terms of Value (V-Shaped Recovery)
10.13.3 Market in Terms of Value (W-Shaped Recovery)
10.13.4 Market in Terms of Value (U-Shaped Recovery)
10.13.5 Market in Terms of Value (L-Shaped Recovery)
10.14 Middle East & Africa Market Breakdown by Distribution Channel
10.14.1 Market in Terms of Value (Normal Recovery)
10.14.2 Market in Terms of Value (V-Shaped Recovery)
10.14.3 Market in Terms of Value (W-Shaped Recovery)
10.14.4 Market in Terms of Value (U-Shaped Recovery)
10.14.5 Market in Terms of Value (L-Shaped Recovery)
10.15 Middle East & Africa Market Breakdown by Age Group
10.15.1 Market in Terms of Value (Normal Recovery)
10.15.2 Market in Terms of Value (V-Shaped Recovery)
10.15.3 Market in Terms of Value (W-Shaped Recovery)
10.15.4 Market in Terms of Value (U-Shaped Recovery)
10.15.5 Market in Terms of Value (L-Shaped Recovery)
11. Latin America Vaccines Sales Market Outlook
11.1 Latin America Market Overview
11.2 Latin America Market in Terms of Value
11.2.1 Market in Terms of Value (Normal Recovery)
11.2.2 Market in Terms of Value (V-Shaped Recovery)
11.2.3 Market in Terms of Value (W-Shaped Recovery)
11.2.4 Market in Terms of Value (U-Shaped Recovery)
11.2.5 Market in Terms of Value (L-Shaped Recovery)
11.3 Latin America Market Breakdown by Country
11.3.1 Market in Terms of Value (Normal Recovery)
11.3.2 Market in Terms of Value (V-Shaped Recovery)
11.3.3 Market in Terms of Value (W-Shaped Recovery)
11.3.4 Market in Terms of Value (U-Shaped Recovery)
11.3.5 Market in Terms of Value (L-Shaped Recovery)
11.4 Brazil Vaccine Sales Market Outlook
11.4.1.1 The Brazilian human vaccines market is the largest in Latin America
11.4.1 Market in Terms of Value (Normal Recovery)
11.4.2 Market in Terms of Value (V-Shaped Recovery)
11.4.3 Market in Terms of Value (W-Shaped Recovery)
11.4.4 Market in Terms of Value (U-Shaped Recovery)
11.4.5 Market in Terms of Value (L-Shaped Recovery)
11.5 Mexico Vaccine Sales Market Outlook
11.5.1 Market in Terms of Value (Normal Recovery)
11.5.2 Market in Terms of Value (V-Shaped Recovery)
11.5.3 Market in Terms of Value (W-Shaped Recovery)
11.5.4 Market in Terms of Value (U-Shaped Recovery)
11.5.5 Market in Terms of Value (L-Shaped Recovery)
11.6 Nigeria Vaccine Sales Market Outlook
11.6.1.1 The market is expected to grow at a decent growth rate during forecast period
11.6.1 Market in Terms of Value (Normal Recovery)
11.6.2 Market in Terms of Value (V-Shaped Recovery)
11.6.3 Market in Terms of Value (W-Shaped Recovery)
11.6.4 Market in Terms of Value (U-Shaped Recovery)
11.6.5 Market in Terms of Value (L-Shaped Recovery)
11.7 Rest of Latin America Vaccine Sales Market Outlook
11.7.1 Market in Terms of Value (Normal Recovery)
11.7.2 Market in Terms of Value (V-Shaped Recovery)
11.7.3 Market in Terms of Value (W-Shaped Recovery)
11.7.4 Market in Terms of Value (U-Shaped Recovery)
11.7.5 Market in Terms of Value (L-Shaped Recovery)
11.8 Latin America Market Breakdown by Disease Type
11.8.1 Market in Terms of Value (Normal Recovery)
11.8.2 Market in Terms of Value (V-Shaped Recovery)
11.8.3 Market in Terms of Value (W-Shaped Recovery)
11.8.4 Market in Terms of Value (U-Shaped Recovery)
11.8.5 Market in Terms of Value (L-Shaped Recovery)
11.9 Latin America Market Breakdown by Viral Diseases
11.9.1 Market in Terms of Value (Normal Recovery)
11.9.2 Market in Terms of Value (V-Shaped Recovery)
11.9.3 Market in Terms of Value (W-Shaped Recovery)
11.9.4 Market in Terms of Value (U-Shaped Recovery)
11.9.5 Market in Terms of Value (L-Shaped Recovery)
11.10 Latin America Market Breakdown by Vaccine Type
11.10.1 Market in Terms of Value (Normal Recovery)
11.10.2 Market in Terms of Value (V-Shaped Recovery)
11.10.3 Market in Terms of Value (W-Shaped Recovery)
11.10.4 Market in Terms of Value (U-Shaped Recovery)
11.10.5 Market in Terms of Value (L-Shaped Recovery)
11.11 Latin America Market Breakdown by Bacterial Diseases
11.11.1 Market in Terms of Value (Normal Recovery)
11.11.2 Market in Terms of Value (V-Shaped Recovery)
11.11.3 Market in Terms of Value (W-Shaped Recovery)
11.11.4 Market in Terms of Value (U-Shaped Recovery)
11.11.5 Market in Terms of Value (L-Shaped Recovery)
11.12 Latin America Market Breakdown by Distribution Channel
11.12.1 Market in Terms of Value (Normal Recovery)
11.12.2 Market in Terms of Value (V-Shaped Recovery)
11.12.3 Market in Terms of Value (W-Shaped Recovery)
11.12.4 Market in Terms of Value (U-Shaped Recovery)
11.12.5 Market in Terms of Value (L-Shaped Recovery)
11.13 Latin America Market Breakdown by Age Group
11.13.1 Market in Terms of Value (Normal Recovery)
11.13.2 Market in Terms of Value (V-Shaped Recovery)
11.13.3 Market in Terms of Value (W-Shaped Recovery)
11.13.4 Market in Terms of Value (U-Shaped Recovery)
11.13.5 Market in Terms of Value (L-Shaped Recovery)
12. Vaccines Under Research & Development
12.1 Dengue Vaccine Research
12.1.1 Status of vaccine development
12.1.2 Challenges to Vaccine Development
12.1.3 WHO activities
12.2 Malaria vaccines
12.2.1 Status of vaccine development
12.3 HIV Vaccine Development
12.4 Meningitis Vaccine Development
12.5 Influenza vaccines
12.5.1 Influenza Vaccine Development
12.5.2 Status of Vaccine Development
12.5.3 Challenges to Vaccine Development
12.6 Tuberculosis Vaccine Development
12.7 Zika Virus Vaccine Product Development
12.7.1 Technical roadmap for Zika vaccine development
12.8 Group A Streptococcus
12.9 RSV Vaccine Research And Development
13. Leading Company Profiles
13.1 Recent Technologies and Companies
13.2 Market Share
13.3 AstraZeneca
13.3.1 AstraZeneca: Business Overview
13.3.2 AstraZeneca: Company Financial Profile
13.3.3 AstraZeneca: Product and Service Offerings
13.3.4 AstraZeneca: Recent Developments
13.4 Johnson & Johnson
13.4.1 Johnson & Johnson: Business Overview
13.4.2 Johnson & Johnson: Company Financial Profile
13.4.3 Johnson & Johnson: Product and Service Offerings
13.4.4 Johnson & Johnson: Recent Developments
13.5 Bavarian Nordic
13.5.1 Bavarian Nordic: Business Overview
13.5.2 Bavarian Nordic: Company Financial Profile
13.5.3 Bavarian Nordic: Product and Service Offerings
13.5.4 Bavarian Nordic: Recent Developments
13.6 Merck & Co.
13.6.1 Merck & Co.: Business Overview
13.6.2 Merck & Co.: Company Financial Profile
13.6.3 Merck & co.: Product and Service Offerings
ERVEBO
13.6.4 Merck & co.: Recent Developments
13.7 Takeda Pharmaceutical Company
13.7.1 Takeda Pharmaceutical Company: Business Overview
13.7.2 Takeda Pharmaceutical Company: Company Financial Profile
13.7.3 Takeda Pharmaceutical Company: Product and Service Offerings
13.7.4 Takeda Pharmaceutical Company: Recent Developments
13.8 Roche Holding AG
13.8.1 Roche Holding AG: Business Overview
13.8.2 Roche Holding AG: Company Financial Profile
13.8.3 Roche Holding AG: Product and Service Offerings
13.8.4 Roche Holding AG: Recent Developments
13.9 GlaxoSmithKline PLC (GSK)
13.9.1 GlaxoSmithKline PLC (GSK): Business Overview
13.9.2 GlaxoSmithKline PLC (GSK): Company Financial Profile
13.9.3 GlaxoSmithKline PLC (GSK): Product and Service Offerings
13.9.4 GlaxoSmithKline PLC (GSK): Recent Developments
13.10 Bayer Inc.
13.10.1 Bayer Inc.: Business Overview
13.10.2 Bayer Inc.: Company Financial Profile
13.10.3 Bayer Inc.: Product and Service Offerings
13.10.4 Bayer Inc.: Recent Developments
13.11 Eli Lilly and Company
13.11.1 Eli Lilly and Company: Business Overview
13.11.2 Eli Lilly and Company: Company Financial Profile
13.11.3 Eli Lilly and Company: Product and Service Offerings
13.11.4 Eli Lilly and Company: Recent Developments
13.12 Bristol-Myers Squibb
13.12.1 Bristol-Myers Squibb: Business Overview
13.12.2 Bristol-Myers Squibb: Company Financial Profile
13.12.3 Bristol-Myers Squibb: Product and Service Offerings
13.12.4 Bristol-Myers Squibb: Recent Developments
13.13 Pfizer Inc.
1.11.1 Pfizer Inc.: Business Overview
13.13.1 Pfizer Inc.: Company Financial Profile
13.13.2 Pfizer Inc.: Product and Service Offerings
13.13.3 Pfizer Inc.: Recent Developments
13.14 Emergent BioSolutions Inc.
13.14.1 Emergent BioSolutions Inc.: Business Overview
13.14.2 Emergent BioSolutions Inc.: Company Financial Profile
13.14.3 Emergent BioSolutions Inc.: Product and Service Offerings
13.14.4 Emergent BioSolutions Inc.: Recent Developments
13.15 Fresenius SE & Co KGaA
13.15.1 Fresenius SE & Co KGaA: Business Overview
13.15.2 Fresenius SE & Co KGaA: Company Financial Profile
13.15.3 Fresenius SE & Co KGaA: Product and Service Offerings
13.15.4 Fresenius SE & Co KGaA: Recent Developments
13.16 Sanofi
13.16.1 Sanofi: Business Overview
13.16.2 Sanofi: Company Financial Profile
13.16.3 Sanofi: Product and Service Offerings
13.16.4 Sanofi: Recent Developments
13.17 BiondVaxPharmaceuticals Ltd.
13.17.1 BiondVax Pharmaceuticals Ltd.: Business Overview
13.17.2 BiondVax Pharmaceuticals Ltd.: Company Financial Profile
13.17.3 BiondVax Pharmaceuticals Ltd.: Product and Service Offerings
13.17.4 BiondVax Pharmaceuticals Ltd.: Recent Developments
14. Conclusion & Recommendations
List of Figures
Figure 1.1 Global Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %)
Figure 6.1 Global Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %)
Figure 6.2 Global Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 6.3 Global Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 6.4 Global Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 6.5 Global Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 6.6 Global Vaccine Sales Market by Region Forecast 2020-2030 (US$ billion, AGR %)
Figure 6.7 Global Vaccine Sales Market by Region Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 6.8 Global Vaccine Sales Market by Region Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 6.9 Global Vaccine Sales Market by Region Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 6.10 Global Vaccine Sales Market by Region Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 6.11 Global Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %)
Figure 6.12 Global Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 6.13 Global Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 6.14 Global Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 6.15 Global Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 6.16 Global Vaccine Sales Market by Viral Disease Forecast 2020-2030 (US$ billion, AGR %)
Figure 6.17 Global Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 6.18 Global Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 6.19 Global Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 6.20 Global Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 6.21 Global Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %)
Figure 6.22 Global Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 6.23 Global Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 6.24 Global Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 6.25 Global Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 6.26 Global Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %)
Figure 6.27 Global Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 6.28 Global Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 6.29 Global Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 6.30 Global Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 6.31 Global Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %)
Figure 6.32 Global Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 6.33 Global Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 6.34 Global Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 6.35 Global Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 6.36 Global Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %)
Figure 6.37 Global Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 6.38 Global Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 6.39 Global Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 6.40 Global Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 7.1 North America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %)
Figure 7.2 North America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 7.3 North America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %)(W-Shaped Recovery)
Figure 7.4 North America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 7.5 North America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 7.6 North America Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %)
Figure 7.7 North America Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 7.8 North America Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 7.9 North America Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 7.10 North America Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 7.11 North America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %)
Figure 7.12 North America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 7.13 North America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 7.14 North America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 7.15 North America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 7.16 North America Vaccine Sales Market by Viral Disease Forecast 2020-2030 (US$ billion, AGR %)
Figure 7.17 North America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 7.18 North America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 7.19 North America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 7.20 North America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 2.1 North America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %)
Figure 7.22 North America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 7.23 North America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 7.24 North America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 7.25 North America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 7.26 North America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %)
Figure 7.27 North America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 7.28 North America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 7.29 North America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 7.30 North America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 7.31 North America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %)
Figure 7.32 North America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 7.33 North America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 7.34 North America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 7.35 North America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 7.36 North America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %)
Figure 7.37 North America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 7.38 North America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 7.39 North America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 7.40 North America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 8.1 Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %)
Figure 8.2 Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 8.3 Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 8.4 Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 8.5 Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 8.6 Europe Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %)
Figure 8.7 Europe Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 8.8 Europe Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 8.9 Europe Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 8.10 Europe Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 8.11 Europe Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %)
Figure 8.12 Europe Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 8.13 Europe Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 8.14 Europe Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 8.15 Europe Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 8.16 Europe Vaccine Sales Market by Viral Disease Forecast 2020-2030 (US$ billion, AGR %)
Figure 8.17 Europe Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 8.18 Europe Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 8.19 Europe Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 8.20 Europe Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 8.21 Europe Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %)
Figure 8.22 Europe Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 8.23 Europe Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 8.24 Europe Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 8.25 Europe Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 8.26 Europe Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %)
Figure 8.27 Europe Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 8.28 Europe Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 8.29 Europe Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 8.30 Europe Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 8.31 Europe Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %)
Figure 8.32 Europe Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 8.33 Europe Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 8.34 Europe Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 8.35 Europe Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 8.36 Europe Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %)
Figure 8.37 Europe Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 8.38 Europe Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 8.39 Europe Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 8.40 Europe Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 9.1 Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %)
Figure 9.2 Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 9.3 Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 9.4 Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 9.5 Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 9.6 Asia-Pacific Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %)
Figure 9.7 Asia-Pacific Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 9.8 Asia-Pacific Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 9.9 Asia-Pacific Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 9.10 Asia-Pacific Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 9.11 Asia-Pacific Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %)
Figure 9.12 Asia-Pacific Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 9.13 Asia-Pacific Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 9.14 Asia-Pacific Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 9.15 Asia-Pacific Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 9.16 Asia-Pacific Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %)
Figure 9.17 Asia-Pacific Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 9.18 Asia-Pacific Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 9.19 Asia-Pacific Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 9.20 Asia-Pacific Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 9.21 Asia-Pacific Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %)
Figure 9.22 Asia-Pacific Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 9.23 Asia-Pacific Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 9.24 Asia-Pacific Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 9.25 Asia-Pacific Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 9.26 Asia-Pacific Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %)
Figure 9.27 Asia-Pacific Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 9.28 Asia-Pacific Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 9.29 Asia-Pacific Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 9.30 Asia-Pacific Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 9.31 Asia-Pacific Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %)
Figure 9.32 Asia-Pacific Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 9.33 Asia-Pacific Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 9.34 Asia-Pacific Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 9.35 Asia-Pacific Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 9.36 Asia-Pacific Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %)
Figure 9.37 Asia-Pacific Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 9.38 Asia-Pacific Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 9.39 Asia-Pacific Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 9.40 Asia-Pacific Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 10.1 Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %)
Figure 10.2 Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 10.3 Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 10.4 Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 10.5 Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 10.6 Middle East & Africa Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %)
Figure 10.7 Middle East & Africa Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 10.8 Middle East & Africa Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 10.9 Middle East & Africa Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 10.10 Middle East & Africa Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 10.11 Middle East & Africa Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %)
Figure 10.12 Middle East & Africa Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 10.13 Middle East & Africa Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 10.14 Middle East & Africa Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 10.15 Middle East & Africa Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 10.16 Middle East & Africa Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %)
Figure 10.17 Middle East & Africa Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 10.18 Middle East & Africa Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 10.19 Middle East & Africa Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 10.20 Middle East & Africa Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 10.21 Middle East & Africa Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %)
Figure 10.22 Middle East & Africa Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 10.23 Middle East & Africa Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 10.24 Middle East & Africa Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 10.25 Middle East & Africa Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 10.26 Middle East & Africa Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %)
Figure 10.27 Middle East & Africa Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 10.28 Middle East & Africa Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 10.29 Middle East & Africa Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 10.30 Middle East & Africa Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 10.31 Middle East & Africa Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %)
Figure 10.32 Middle East & Africa Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 10.33 Middle East & Africa Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 10.34 Middle East & Africa Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 10.35 Middle East & Africa Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 10.36 Middle East & Africa Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %)
Figure 10.37 Middle East & Africa Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 10.38 Middle East & Africa Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 10.39 Middle East & Africa Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 10.40 Middle East & Africa Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 11.1 Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %)
Figure 11.2 Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 11.3 Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 11.4 Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 11.5 Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 11.6 Latin America Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %)
Figure 11.7 Latin America Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 11.8 Latin America Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 11.9 Latin America Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 11.10 Latin America Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 11.11 Latin America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %)
Figure 11.12 Latin America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %)
Figure 11.13 Latin America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 11.14 Latin America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 11.15 Latin America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 11.16 Latin America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %)
Figure 11.17 Latin America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 11.18 Latin America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 11.19 Latin America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 11.20 Latin America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 11.21 Latin America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %)
Figure 11.22 Latin America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 11.23 Latin America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 11.24 Latin America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 11.25 Latin America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 11.26 Latin America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %)
Figure 11.27 Latin America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 11.28 Latin America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 11.29 Latin America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 11.30 Latin America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 11.31 Latin America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %)
Figure 11.32 Latin America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 11.33 Latin America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 11.34 Latin America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 11.35 Latin America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 11.36 Latin America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %)
Figure 11.37 Latin America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)
Figure 11.38 Latin America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)
Figure 11.39 Latin America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)
Figure 11.40 Latin America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)
Figure 12.1 Dengue Vaccine Candidates in the Development
Figure 13.1 Global Vaccine Sales Market Share 2019 (%)
Figure13.2AstraZeneca: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure13.3AstraZeneca: Company Operating Income 2015-2019 (US$Mn)
Figure13.4AstraZeneca: Company EBITDA 2015-2019 (US$Mn)
Figure13.5AstraZeneca: Company Net Income/Loss 2015-2019 (US$Mn)
Figure13.6Johnson & Johnson: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure13.7Johnson & Johnson: Company Operating Income 2015-2019 (US$Mn)
Figure13.8Johnson & Johnson: Company EBITDA 2015-2019 (US$Mn)
Figure13.9 Johnson & Johnson: Company Net Income/Loss 2015-2019 (US$Mn)
Figure13.10Bavarian Nordic: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure11.10Bavarian Nordic: Company Operating Income 2015-2019 (US$Mn)
Figure13.12Bavarian Nordic: Company EBITDA 2015-2019 (US$Mn)
Figure13.13Bavarian Nordic: Company Net Income/Loss 2015-2019 (US$Mn)
Figure131.141Bayer Inc.: Company EBITDA 2015-2019 (US$Mn)
Figure 13.15 Sanofi: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure13.16Sanofi: Company Operating Income 2015-2019 (US$Mn)
Figure 13.17 Sanofi: Company EBITDA 2015-2019 (US$Mn)
Figure 13.18Sanofi: Company Net Income/Loss 2015-2019 (US$Mn)
List of Tables
Table 1.1 Global Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 2.1 Global Vaccine Sales Market Summary Table
Table 3.1 History of Vaccines
Table 1.1 COVID-19 Therapeutic Interventions in Development, by Biopharmaceutical Company Collaborations
Table 1.1 COVID-19 Therapeutics in Development, by Biopharmaceutical Company
Table 1.1 COVID-19 Vaccines in Development by Biopharmaceutical Companies in Collaboration
Table 1.1 COVID-19 Vaccines in Development, by Biopharmaceutical Company
Table 6.1 UNICEF Vaccination Price and Major Suppliers, 2019
Table 6.2 Global Vaccine Price List, 2019
Table 6.3 Global Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 6.4 Global Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 6.5 Global Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 6.6 Global Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 6.7 Global Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 6.8 Global Vaccine Sales Market by Region Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 6.9 Global Vaccine Sales Market by Region Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 6.10 Global Vaccine Sales Market by Region Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 6.11 Global Vaccine Sales Market by Region Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 6.12 Global Vaccine Sales Market by Region Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 6.13 Global Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 6.14 Global Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 6.15 Global Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 6.16 Global Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 6.17 Global Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 6.18 Vaccine-Preventable Human Viral Diseases
Table 6.19 Vaccines, by Disease Type
Table 6.20 Seasonal Influenza Vaccines
Table 6.21 Global Vaccine Sales Market by Viral Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 6.22 Global Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 6.23 Global Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 6.24 Global Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 6.25 Global Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 6.26 Types of Attenuated (Live) Vaccines
Table 6.27 Advantages and Disadvantages of Attenuated (Live) Vaccines
Table 6.28 Types of Inactivated (Killed) Vaccines
Table 6.29 Advantages and Disadvantages of Inactivated (Killed) Vaccines
Table 6.30 Types of Toxoid Vaccines
Table 6.31 Advantages and Disadvantages of Toxoid Vaccines
Table 6.32 Types of Subunit Vaccines
Table 6.33 Advantages and Disadvantages of Subunit Vaccines
Table 6.34 Types of Conjugate Vaccines
Table 5.30 Advantages and Disadvantages of Conjugate Vaccines
Table 6.36 Types of Recombinant Vector Vaccines
Table 6.37 Advantages and Disadvantages of Recombinant Vector Vaccines
Table 6.38 Types of DNA Vaccines
Table 6.39 Advantages and Disadvantages of DNA Vaccines
Table 6.40 Advantages and Disadvantages of RNA Vaccines
Table 6.41 Vaccine Excipient and Media Summary, Excipients included in U.S. Vaccines
Table 6.42 Global Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 6.43 Global Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 6.44 Global Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 6.45 Global Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 6.46 Global Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 6.47 Vaccine-Preventable Human Bacterial Diseases
Table 6.48 Global Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 6.49 Global Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 6.50 Global Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 6.51 Global Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 6.52 Global Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 6.53 Global Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 6.54 Global Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 6.55 Global Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 6.56 Global Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 6.57 Global Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 6.58 Pediatric Vaccines Doses
Table 6.59 Pediatric/VFC Vaccine Price List, 2019
Table 6.60 Pediatric Influenza Vaccine Price List
Table 6.61 Vaccines Dose by Age
Table 6.62 Adult Vaccine Price List
Table 6.63 Global Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 6.64 Global Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 6.65 Global Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 6.66 Global Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 6.67 Global Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 7.1 North America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 7.2 North America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 7.3 North America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 7.4 North America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 7.5 North America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 7.6 US Recommended Immunization Schedule, by Vaccine Type, 2020
Table 7.7 U.S. Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 7.8 U.S. Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 7.9 U.S. Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 7.10 U.S. Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 7.11 U.S. Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 7.12 Immunization Schedule of Canada, 2020
Table 7.13 Canada Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 7.14 Canada Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 7.15 Canada Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 7.16 Canada Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 7.17 Canada Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 7.18 North America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 7.19 North America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 7.20 North America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 7.21 North America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 7.22 North America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 7.23 North America Vaccine Sales Market by Viral Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 7.24 North America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 7.25 North America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 7.26 North America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 7.27 North America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 7.28 North America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 7.29 North America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 7.30 North America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 7.31 North America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 7.32 North America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 7.33 North America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 7.34 North America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 7.35 North America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 7.36 North America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 7.37 North America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 7.38 North America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 7.39 North America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 7.40 North America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 7.41 North America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 7.42 North America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 7.43 North America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 7.44 North America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 7.45 North America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 7.46 North America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 7.47 North America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 8.1 Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 8.2 Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 8.3 Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 8.4 Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 8.5 Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 8.6 Russia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 8.7 Russia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 8.8 Russia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 8.9 Russia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 8.10 Russia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 8.11 Immunization Schedule of Germany, 2020
Table 8.12 Germany Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 8.13 Germany Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 8.14 Germany Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 8.15 Germany Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 8.16 Germany Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 8.17 UK Vaccine Schedules
Table 8.18 UK Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 8.19 UK Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 8.20 UK Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 8.21 UK Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 8.22 UK Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 8.23 Immunization Schedule of France, 2020
Table 8.24 France Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 8.25 France Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 8.26 France Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 8.27 France Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 8.28 France Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 8.29 Immunization Schedule of Italy, 2020
Table 8.30 Italy Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 8.31 Italy Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 8.32 Italy Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 8.33 Italy Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 8.34 Italy Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 8.35 Rest of Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 8.36 Rest of Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 8.37 Rest of Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 8.38 Rest of Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 8.39 Rest of Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 8.40 Europe Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 8.41 Europe Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 8.42 Europe Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 8.43 Europe Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 8.44 Europe Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 8.45 Europe Vaccine Sales Market by Viral Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 8.46 Europe Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 8.47 Europe Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 8.48 Europe Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 8.49 Europe Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 8.50 Europe Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 8.51 Europe Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 8.52 Europe Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 8.53 Europe Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 8.54 Europe Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 8.55 Europe Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 8.56 Europe Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 8.57 Europe Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 8.58 Europe Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 8.59 Europe Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 8.60 Europe Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 8.61 Europe Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 8.62 Europe Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 8.63 Europe Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 8.64 Europe Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 8.65 Europe Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 8.66 Europe Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 8.67 Europe Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 8.68 Europe Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 8.69 Europe Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.1 Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 9.2 Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.3 Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.4 Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.5 Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.6 Vaccination and Immunization Schedule of China, 2020
Table 9.7 China Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 9.8 China Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.9 China Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.10 China Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.11 China Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.12 Immunization Schedule of Japan, 2020
Table 9.13 Japan Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 9.14 Japan Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.15 Japan Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.16 Japan Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.17 Japan Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.18 Immunization Schedule of India, 2020
Table 9.19 GAVI Support to India, 2001-2021
Table 9.20 India Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 9.21 India Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.22 India Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.23 India Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.24 India Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.25 South Korea Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 9.26 South Korea Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.27 South Korea Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.28 South Korea Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.29 South Korea Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.30 Australia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 9.31 Australia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.32 Australia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.33 Australia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.34 Australia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.35 Rest of Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 9.36 Rest of Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.37 Rest of Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.38 Rest of Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.39 Rest of Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.40 Asia-Pacific Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 9.41 Asia-Pacific Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.42 Asia-Pacific Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.43 Asia-Pacific Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.44 Asia-Pacific Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.45 Asia-Pacific Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 9.46 Asia-Pacific Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.47 Asia-Pacific Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.48 Asia-Pacific Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.49 Asia-Pacific Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.50 Asia-Pacific Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 9.51 Asia-Pacific Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.52 Asia-Pacific Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.53 Asia-Pacific Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.54 Asia-Pacific Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.55 Asia-Pacific Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 9.56 Asia-Pacific Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.57 Asia-Pacific Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.58 Asia-Pacific Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.59 Asia-Pacific Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.60 Asia-Pacific Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 9.61 Asia-Pacific Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.62 Asia-Pacific Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.63 Asia-Pacific Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.64 Asia-Pacific Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.65 Asia-Pacific Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 9.66 Asia-Pacific Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.67 Asia-Pacific Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.68 Asia-Pacific Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.69 Asia-Pacific Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.1 Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 10.2 Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.3 Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.4 Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.5 Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.6 Turkey Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 10.7 Turkey Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.8 Turkey Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.9 Turkey Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.10 Turkey Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.11 Saudi Arabia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 10.12 Saudi Arabia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.13 Saudi Arabia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.14 Saudi Arabia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.15 Saudi Arabia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.16 South Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 10.17 South Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.18 South Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.19 South Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.20 South Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.21 Iran Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 10.22 Iran Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.23 Iran Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.24 Iran Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.25 Iran Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.26 UAE Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 10.27 UAE Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.28 UAE Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.29 UAE Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.30 UAE Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.31 Rest of Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 10.32 Rest of Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.33 Rest of Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.34 Rest of Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.35 Rest of Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.36 Middle East & Africa Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 10.37 Middle East & Africa Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.38 Middle East & Africa Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.39 Middle East & Africa Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.40 Middle East & Africa Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.41 Middle East & Africa Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 10.42 Middle East & Africa Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.43 Middle East & Africa Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.44 Middle East & Africa Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.45 Middle East & Africa Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.46 Middle East & Africa Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 10.47 Middle East & Africa Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.48 Middle East & Africa Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.49 Middle East & Africa Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.50 Middle East & Africa Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.51 Middle East & Africa Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 10.52 Middle East & Africa Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.53 Middle East & Africa Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.54 Middle East & Africa Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.55 Middle East & Africa Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.56 Middle East & Africa Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 10.57 Middle East & Africa Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.58 Middle East & Africa Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.59 Middle East & Africa Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.60 Middle East & Africa Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.61 Middle East & Africa Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 10.62 Middle East & Africa Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.63 Middle East & Africa Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.64 Middle East & Africa Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.65 Middle East & Africa Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.1 Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 11.2 Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.3 Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.4 Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.5 Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.6 Brazil Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 11.7 Brazil Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.8 Brazil Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.9 Brazil Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.10 Brazil Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.11 Mexico Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 11.12 Mexico Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.13 Mexico Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.14 Mexico Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.15 Mexico Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.16 Nigeria Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 11.17 Nigeria Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.18 Nigeria Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.19 Nigeria Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.20 Nigeria Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.21 Rest of Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 11.22 Rest of Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.23 Rest of Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.24 Rest of Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.25 Rest of Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.26 Latin America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 11.27 Latin America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 11.28 Latin America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.29 Latin America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.30 Latin America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.31 Latin America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 11.32 Latin America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.33 Latin America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.34 Latin America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.35 Latin America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.36 Latin America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 11.37 Latin America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.38 Latin America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.39 Latin America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.40 Latin America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.41 Latin America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 11.42 Latin America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.43 Latin America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.44 Latin America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.45 Latin America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.46 Latin America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 11.47 Latin America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.48 Latin America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.49 Latin America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.50 Latin America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.51 Latin America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %)
Table 11.52 Latin America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.53 Latin America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.54 Latin America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.55 Latin America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)
Table13.1 AstraZeneca Company Information
Table13.2 AstraZeneca: Company Revenue 2015-2019 (US$Mn, AGR %)
Table13.3 AstraZeneca: Company Product and Service Offerings
Table13.4 AstraZeneca: Company Recent Developments till July,2020
Table13.5 Johnson & Johnson Company Information
Table13.6 Johnson & Johnson: Company Revenue 2015-2019 (US$Mn, AGR %)
Table13.7 Johnson & Johnson: Company Product and Service Offerings
Table13.8 Johnson & Johnson: Company Recent Developments till July,2020
Table13.9 Bavarian Nordic Company Information
Table13.10 Bavarian Nordic: Company Revenue 2015-2019 (US$Mn, AGR %)
Table13.11 Bavarian Nordic: Company Product and Service Offerings
Table13.12 Bavarian Nordic: Company Recent Developments till July,2020
Table13.13 Merck & Co.Company Information
Table13.14 Merck & Co.: Company Revenue 2015-2019 (US$Mn, AGR %)
Table13.15 Merck & co.: Company Product and Service Offerings
Table13.16 Merck & co.: Company Recent Developments till July,2020
Table13.17 Takeda Pharmaceutical: Company Information
Table13.18 Takeda Pharmaceutical Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Table13.19 Takeda Pharmaceutical Company: Company Product and Service Offerings
Table13.20 Takeda Pharmaceutical Company: Company Recent Developments till July,2020
Table13.21 Roche Holding AG Company Information
Table113.22 Roche Holding AG: Company Recent Developments till July,2020
Table113.23 GlaxoSmithKline PLC (GSK) Company Information
Table131.24 GlaxoSmithKline PLC (GSK): Company Revenue 2015-2019 (US$Mn, AGR %)
Table113.25 GlaxoSmithKline PLC (GSK): Company Product and Service Offerings
Table113.26 GlaxoSmithKline PLC (GSK): Company Recent Developments till July,2020
Table113.27 Bayer Inc. Company Information
Table113.28 Bayer Inc.: Company Product and Service Offerings
Table131.29 Bayer Inc.: Company Recent Developments till July,2020
Table113.30 Eli Lilly and Company Company Information
Table113.31 Eli Lilly and Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Table113.32 Eli Lilly and Company: Company Product and Service Offerings
Table113.33 Eli Lilly and Company: Company Recent Developments till July,2020
Table113.34 Bristol-Myers Squibb Company Information
Table131.35 Bristol-Myers Squibb: Company Revenue 2015-2019 (US$Mn, AGR %)
Table113.36 Bristol-Myers Squibb: Company Product and Service Offerings
Table113.37 Bristol-Myers Squibb: Company Recent Developments till July,2020
Table 13.38 Pfizer Inc.: Company Revenue 2015-2019 (US$Mn, AGR %)
Table13.39 Pfizer Inc.: Company Product and Service Offerings
Table13.40 Pfizer Inc.: Company Recent Developments till July,2020
Table 13.41 Emergent BioSolutions Inc. Company Information
Table 13.42 Emergent BioSolutions Inc.: Company Revenue 2015-2019 (US$Mn, AGR %)
Table 13.43 Emergent BioSolutions Inc.: Company Product and Service Offerings
Table 13.44 Emergent BioSolutions Inc.: Company Recent Developments till July,2020
Table 13.45 Fresenius SE & Co KGaA Company Information
Table 11.50 Fresenius SE & Co KGaA: Company Revenue 2015-2019 (US$Mn, AGR %)
List of Companies Profiled
AstraZeneca
Bavarian Nordic
Bayer
BiondVax
Bristol-Myers Squibb
Eli Lilly
Emergent BioSolutions Inc.
Fresenius
GlaxoSmithKline (GSK)
Johnson & Johnson
Merck & Co.
Pfizer
Roche
Sanofi Pasteur
Takeda
List of Other Companies
Abbott Biologicals BV
Adimmune
AJ Vaccines A/S
Arabio
AstraZeneca
Bavarian Nordic
Beijing Institute of Biological Products Co., Ltd. (CNBG Subsidiary)
Beijing Minhai Biotec Group
Bharat Biotech International Limited
Biken Co. Ltd.
Bilthoven Biologicals
Binnopharm
Bio-Manguinhos/Fiocruz
Bio-Med
BioKantai
Biological E. Limited
Biomed Lublin
BIRMEX
Boryung
Bul Bio - National Center of Infectious and Parasitic Diseases Ltd.
Cadila Health Care LTD
Changchun BCHT
Changchun Institute of Biological Products Co.,Ltd (CNBG Subsidiary)
Changchun Keygen Biological Products Co.,Ltd (CNBG Subsidiary)
Changchun Wes-bio
Changchun Zuoyi
Cheng Da Biotechnology
Chengdu Institute of Biological Products Co.,Ltd (CNBG Subsidiary)
Chengdu Kanghua
Chinese Academy of Medical Sciences Institute of Medical Biology
Chiron Behring Vaccines Private Ltd.
Chongqing Zhifei Biological Products Co Ltd
Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products of Russian Academy of Sciences
Convac
Daiichi Sankyo
Dalian Hissen
EuBiologics Co., Ltd.
Ezequiel Dias Foundation (FUNED)
Finlay Institute
Fundacao Ataulpho de Paiva
GlaxoSmithKline Biologicals SA
GPO-MBP Co., Ltd.
Green Cross Corporation
GreenSignal Bio Pharma Limited
Guanzhou Connaught
Haffkine Bio Pharmaceutical Corporation Ltd
HLL Biotech Limited
Hualan Biological Bacterin Co., Ltd
IBSS Biomed
IL-YANG PHARMACEUTICAL CO., LTD.
Incepta vaccine
Indian Immunologicals Ltd
Institut Pasteur de Dakar
Institut Pasteur de Tunis
Institut Pasteur Iran
Institute of Vaccines and Medical Biologicals
Institute Rafael Rangel Caracas
Instituto Butantan
Intervax
Janssen Vaccines Corp.
Japan BCG Laboratory
KM Biologics Co. Ltd.
Korea Vaccine
Lanzhou Institute of Biological Products Co., Ltd (CNBG Subsidiary)
LG Chem Ltd
MassBiologics
Merck Vaccines
Merck Vaccines/Sanofi Pasteur vaccine
Microgen
Ministry of Defense, Russia
Mitsubishi Tanabe Pharma
North China Pharmaceutical Group
Olymvax Biopharmaceuticals
Panacea Biotec Ltd.
PaxVax
Petrovax
Pfizer
POLYVAC
PT Bio Farma (Persero)
Razi Vaccine & Serum Research Institute
Rongan Biological
Royal (Wuxi) Bio-Pharmaceutical
Sanofi Pasteur
Seqirus Limited
Serum Institute of India Pvt. Ltd.
Shanghai Fosun
Shanghai Institute of Biological Products Co.,Ltd (CNBG Subsidiary)
Shanghai Rongsheng Biotech
Shanghai United Cell Biotechnology
Shantha Biotechnics Private Limited (A Sanofi Company)
Shichuan Yuanda
Sinovac Biotech Co. Ltd
SK Bioscience Co., Ltd.
Takeda
Thai Red Cross
Torlak
VABIOTECH
Vacsera
Valneva
Vector-BiAlgam
Walvax
Wuhan Institute of Biological Products Co., Ltd (CNBG Subsidiary)
Zhejiang Pukang Biology
Zhejiang Weixin
ZhongKe Biopharm Co.
List of Organizations Mentioned in the Report
Centers for Disease Control and Protection (CDC)
Centre for Biologics Evaluation and Research (CBER)
Developing Countries Vaccine Manufacturers Network (DCVMN)
European Medicines Agency (EMA)
Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
Food and Drug Administration (FDA)
Global Alliance for Vaccines
Global Alliance for Vaccines and Immunization (GAVI)
International Financing Facility for Immunisation
National Health Service (NHS)
Pan American Health Organization (PAHO)
The Butantan Institute
The Indian Department of Biotech
The Ministry of Health, Labour and Welfare and the Health Service Bureau
UNICEF
World Health Organization (WHO)
Download sample pages
Complete the form below to download your free sample pages for Vaccines Sales Market Report 2020-2030Related reports
-
Vaccine Adjuvants Market Report 2021-2031
The opportunity for innovation within the vaccine adjuvants market remains strong. As time progresses, the technology used in the manufacturing...Full DetailsPublished: 02 February 2021 -
Vaccine Delivery Devices Market Report 2021-2031
Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product...Full DetailsPublished: 06 January 2021 -
Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Report 2021-2031
Contract manufacturing outsourcing is gaining attraction owing to growing trend of outsourcing among pharmaceutical businesses. ...Full DetailsPublished: 16 November 2021 -
Stem Cell Technologies and Applications Market Report 2021-2031
Factors such as rising prevalence of chronic and genetic diseases, increasing application areas of stem cell technologies, technological advancements, and...Full DetailsPublished: 10 August 2021 -
Cell-Based Assays Market Report to 2030
Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are...Full DetailsPublished: 04 March 2021 -
Healthcare Cold Chain Logistics Market Report 2020-2030
How will the global healthcare cold chain logistics industry evolve during this unique time? Visiongain’s report tells you 4 unique...
Full DetailsPublished: 09 September 2020 -
Global Live Vaccines Market Forecast 2020-2030
The global live vaccines market was valued at $10,423.4 mn in 2019 and is anticipated to surpass $ 20,020 mn...
Full DetailsPublished: 12 March 2020 -
Novel Coronavirus (COVID-19) Drugs in Development Market Forecast 2020-2030
Our 180+ page report provides 100+ tables, charts, and graphs. Read on to discover the most key areas in the...
Full DetailsPublished: 18 May 2020 -
Biopharmaceuticals Contract Manufacturing Market Report 2020-2030
As of 2019, the global biopharmaceuticals market’s size was estimated at ~$232 billion. It is expected to grow at a...
Full DetailsPublished: 04 March 2020 -
Cellular Immunotherapy Market Report 2021-2031
Increasing prevalence of cancers and rising demand for advanced therapies for cancer treatment are the major factors driving the demand...Full DetailsPublished: 08 June 2021
Download sample pages
Complete the form below to download your free sample pages for Vaccines Sales Market Report 2020-2030Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: jamie.roberts@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Jamie Roberts stating your chosen report title to jamie.roberts@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email jamie.roberts@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Drug Delivery Technologies Market Report 2024-2034
The global Drug Delivery Technologies market is estimated at US$1,729.6 billion in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period 2024-2034.
23 April 2024
Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034
The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.
18 April 2024
Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034
The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.
17 April 2024
Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034
The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.
12 April 2024
